ASTM E2500-25 PDF
Name in English:
St ASTM E2500-25
Name in Russian:
Ст ASTM E2500-25
Original standard ASTM E2500-25 in PDF full version. Additional info + preview on request
Full title and description
Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment — Science- and Risk-Based Approach. This guide provides a framework for specifying, designing, and verifying manufacturing systems and equipment using a science- and risk-based methodology to ensure systems are fit for intended use and meet regulatory expectations.
Abstract
ASTM E2500-25 defines a lifecycle, science- and risk-based approach to the specification, design, and verification of pharmaceutical and biopharmaceutical manufacturing systems and associated equipment, including process equipment, utilities, monitoring and control systems, and automation. It is applicable to new and existing systems and may be used to support change implementation; it does not substitute for broader facility-level quality risk management activities or address employee safety, environmental, or non‑GxP regulatory requirements.
General information
- Status: Active standard (current revision).
- Publication date: March 15, 2025.
- Publisher: ASTM International.
- ICS / categories: 11.120.99 (Other standards related to pharmaceutics).
- Edition / version: E2500-25 (revises E2500-20).
- Number of pages: 10 pages.
Scope
The guide applies to all elements of pharmaceutical and biopharmaceutical manufacturing systems that can affect product quality, availability, or patient safety — including GMP utilities, process equipment, supporting utilities, monitoring and control systems, and automation. It covers lifecycle activities from concept through retirement and may be applied to laboratory and certain medical device manufacturing systems with noted exceptions (for example, laboratory instrument qualification and software qualification are covered by other documents). It does not address facility‑level contamination control strategies as a whole, nor employee health/safety or non‑GxP environmental regulations.
Key topics and requirements
- Science- and risk-based specification, design, and verification strategies.
- Lifecycle approach: concept, design, installation, operation, performance, change management, and retirement.
- Identification and management of critical aspects and critical design elements that affect product quality and patient safety.
- Verification planning proportional to risk (replacing one-size-fits-all prescriptive qualification with targeted verification activities).
- Documentation and evidence requirements to demonstrate systems are fit for intended use.
- Interfaces with related guidance (laboratory instrument, software qualification, medical device risk management) and regulatory expectations.
Typical use and users
Used by pharmaceutical and biopharmaceutical manufacturers, validation and qualification engineers, quality assurance and regulatory affairs personnel, process and automation engineers, equipment suppliers, and consultants. It is referenced when developing verification strategies, acceptance criteria, test plans, and when documenting that systems are fit for intended use for regulatory submissions and inspections.
Related standards
Commonly referenced documents and complementary standards include the prior edition ASTM E2500-20 (superseded), USP <1058> (laboratory instrument qualification), ISPE GAMP guidance (software and automation), ISO 14971 (medical device risk management) and various national regulatory guidance documents addressing process validation and equipment qualification. Users should cross-reference applicable regulatory guidance for their jurisdiction.
Keywords
risk-based verification, equipment specification, pharmaceutical manufacturing systems, biopharmaceutical, design verification, lifecycle, qualification, critical design elements, GMP utilities, automation, verification strategy.
FAQ
Q: What is this standard?
A: ASTM E2500-25 is a standard guide providing a science‑ and risk‑based framework for specification, design, and verification of pharmaceutical and biopharmaceutical manufacturing systems and equipment.
Q: What does it cover?
A: It covers lifecycle activities for manufacturing systems (specification, design, installation, operation, performance, change and retirement) and emphasizes targeted verification based on risk to demonstrate systems are fit for intended use. It excludes broader facility contamination control strategy and non‑GxP safety/environmental regulations.
Q: Who typically uses it?
A: Validation/qualification engineers, QA and regulatory personnel, process and automation engineers, equipment suppliers, and consultants in the pharmaceutical and biopharmaceutical industries.
Q: Is it current or superseded?
A: Current — the active revision is E2500-25 (published March 15, 2025), which supersedes E2500-20.
Q: Is it part of a series?
A: It is maintained by ASTM Committee E55 (subcommittee E55.11) and belongs to ASTM standards covering pharmaceutical engineering and related guides; users often apply it together with other sector-specific standards and guidance (for example, USP and ISPE GAMP documents).
Q: What are the key keywords?
A: Risk-based verification, specification, design, validation, pharmaceutical manufacturing systems, critical design elements, lifecycle, GMP utilities, automation.